巴西间日疟治疗中G6PD筛查后使用他非诺喹对比伯氨喹的成本效果分析:基于传播模型的研究
该研究利用传播模型评估巴西间日疟在G6PD筛查后使用他非诺喹对比常规实践(7天低剂量伯氨喹0.5 mg/kg/天,不筛查G6PD)的成本效果,时间跨度10年、贴现率5%,考虑4种场景。所有场景在支付意愿阈值7800美元下均具成本效果,ICERs范围为154至1836美元,且100%概率具成本效果。
要点
- 在巴西,G6PD筛查后使用他非诺喹对比不筛查G6PD的7天低剂量伯氨喹常规实践,4种场景下均具成本效果。
- 4种场景的ICERs范围为154至1836美元,均低于巴西7800美元支付意愿阈值。
- 所有场景在支付意愿阈值下具有100%的成本效果概率。
核心结论
- 在纳入传播影响的建模研究中,半定量G6PD检测后处方他非诺喹在巴西极可能具成本效果。
- 这些结果展示了确保安全有效根治对健康和经济潜在的重要性。
研究设计与样本
- 利用传播模型评估巴西间日疟治疗中G6PD筛查后使用他非诺喹对比常规实践的成本效果,时间跨度10年、贴现率5%。
- 常规实践为7天低剂量伯氨喹(0.5 mg/kg/天)且不筛查G6PD。
- 考虑4种场景:仅成人他非诺喹且假设伯氨喹依从性66.7%;成人和>2岁儿童他非诺喹且假设伯氨喹依从性66.7%;仅成人他非诺喹且假设伯氨喹依从性90%;仅成人他非诺喹且假设伯氨喹依从性30%。
- ICERs通过增量成本除以避免的伤残调整生命年(DALYs)估算,并与巴西7800美元支付意愿阈值比较。
- 进行单因素和概率敏感性分析。
主要发现
- 在支付意愿阈值7800美元下,4种场景在基础案例分析中均具成本效果,ICERs范围为154至1836美元。
- 单因素敏感性分析显示结果对间日疟的严重程度和死亡率、半定量G6PD分析仪所需寿命和数量、每例疟疾发作成本和每G6PD检测试纸条成本以及预期寿命最为敏感。
- 所有场景在支付意愿阈值下具有100%的成本效果概率。
关键数值与推荐
- 4种场景的ICERs范围为154至1836美元,均低于巴西支付意愿阈值7800美元。
- 所有场景在支付意愿阈值下具有100%的成本效果概率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性在于低传播环境下成本估计、G6PD筛查成本以及间日疟严重程度相关的参数不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria transmission modelling has demonstrated the potential impact of semiquantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose tafenoquine for Plasmodium vivax radical cure but has not investigated the associated costs. This study evaluated the cost-effectiveness of P. vivax treatment with tafenoquine after G6PD testing using a transmission model. METHODS AND FINDINGS: We explored the cost-effectiveness of using tafenoquine after G6PD screening as compared to usual practice (7-day low-dose primaquine (0.5 mg/kg/day) without G6PD screening) in Brazil using a 10-year time horizon with 5% discounting considering 4 scenarios: (1) tafenoquine for adults only assuming 66.7% primaquine treatment adherence; (2) tafenoquine for adults and children aged >2 years assuming 66.7% primaquine adherence; (3) tafenoquine for adults only assuming 90% primaquine adherence; and (4) tafenoquine for adults only assuming 30% primaquine adherence. The incremental cost-effectiveness ratios (ICERs) were estimated by dividing the incremental costs by the disability-adjusted life years (DALYs) averted. These were compared to a willingness to pay (WTP) threshold of US$7,800 for Brazil, and one-way and probabilistic sensitivity analyses were performed. All 4 scenarios were cost-effective in the base case analysis using this WTP threshold with ICERs ranging from US$154 to US$1,836. One-way sensitivity analyses showed that the results were most sensitive to severity and mortality due to vivax malaria, the lifetime and number of semiquantitative G6PD analysers needed, cost per malaria episode and per G6PD test strips, and life expectancy. All scenarios had a 100% likelihood of being cost-effective at the WTP threshold. The main limitations of this study are due to parameter uncertainty around our cost estimates for low transmission settings, the costs of G6PD screening, and the severity of vivax malaria. CONCLUSIONS: In our modelling study that incorporated impact on transmission, tafenoquine prescribed after a semiquantitative G6PD testing was highly likely to be cost-effective in Brazil. These results demonstrate the potential health and economic importance of ensuring safe and effective radical cure.
引用
- Price DJ, Nekkab N, Monteiro WM, et al. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model. PLoS Med. 2024. PMID: 38194420. doi:10.1371/journal.pmed.1004255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。